Research progresses in novel cancer treatments and biomarker discovery. Genialis partnered with Cleveland Clinic to develop AI-assisted predictive biomarkers for pancreatic cancer therapy responses using RNA sequencing and patient-derived organoids, aiming for precision medicine improvements. Precision Biologics advances PB-vcMMAE-5, an antibody-drug conjugate targeting ovarian cancer by focusing on tumor-specific O-glycans to overcome immune evasion. StratifAI secured €12.5 million to expand clinical validation of its multimodal AI biomarker platform, targeting prognostic markers in breast cancer. These efforts collectively push toward personalized and more effective oncological interventions.